Pentoxifylline Reduces Subclinical Atherosclerosis in Patients with Type 2 Diabetes and Chronic Kidney Disease
Key Findings:
Pentoxifylline (PTF) shows positive effects on the progression of subclinical atherosclerosis (SA) in patients with type 2 diabetes mellitus and chronic kidney disease (CKD).
Practical Solutions:
PTF treatment resulted in improved carotid intima-media thickness (CIMT), increased levels of the cardiovascular health protein Klotho (KL) in blood cells, and reduced inflammation.
Value:
PTF treatment, along with variations in KL expression and changes in HDL, were significant determinants for CIMT progression, independently of traditional risk factors. PTF demonstrates potential as a protective factor against the worsening of CIMT.
Clinical Trial Benefits and Streamlining Healthcare
Importance of Clinical Trials:
Clinical trials are essential for developing safe and effective treatments, and it’s crucial to integrate their benefits into routine medical practice.
Practical Solutions for Healthcare Operations:
Our AI-driven platform, DocSym, consolidates clinical protocols and research into a user-friendly knowledge base for clinicians. Additionally, our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining patient care and expanding digital services.
Value of AI in Healthcare:
By leveraging AI, clinics can improve workflows, enhance patient outcomes, and reduce paper-based routines. Visit aidevmd.com to learn more about how we can support your healthcare practice.
